Better late than never, right? Finally, and after several delays, on Tuesday, Novavax (NVAX) announced it had submitted to the FDA its request for Emergency Use Authorization (EUA) for Covid-19 vaccine NVX-CoV2373.
The setbacks the company had encountered on the path toward the filing mostly revolved around manufacturing issues. As such, B. Riley analyst Mayank Mamtani thinks a “key component” in driving approvals will be “confidence from government agencies in the company’s global manufacturing infrastructure to deliver on the ensuing demand.”
Until now, Novavax’s strategic partner, the Serum Institute of India (SII), has been responsible for the supply of doses. At the last count, which includes the Indian government’s latest export permit of 250 million doses beginning this month, the total tally of doses allocated to be shipped from India has reached over 350 million….
